PT - JOURNAL ARTICLE AU - Ahmad, Riris Andono AU - Indriani, Citra AU - Arisanti, Risalia Reni AU - Nanda, Ratih Oktri AU - Mahendradhata, Yodi AU - Wibawa, Tri TI - Seroprevalence of SARS-CoV-2 and risk factors in Bantul Regency, Yogyakarta, Indonesia AID - 10.1101/2022.06.07.22276128 DP - 2022 Jan 01 TA - medRxiv PG - 2022.06.07.22276128 4099 - http://medrxiv.org/content/early/2022/06/09/2022.06.07.22276128.short 4100 - http://medrxiv.org/content/early/2022/06/09/2022.06.07.22276128.full AB - COVID-19 case counts in Indonesia inevitably underestimate the true cumulative incidence of infection due to limited barriers to testing accessibility and asymptomatic infections. Therefore, community-based serological data are essential for understanding the true prevalence of infections. This study aims to estimate the seroprevalence of SARS-CoV-2 infection and factors related to the seropositivity in Bantul Regency, Yogyakarta, Indonesia. A cross-sectional study involving 425 individuals in 40 clusters was conducted between March and April 2021. Participants were interviewed using an e-questionnaire developed in the Kobo toolbox to collect information on socio-demographic, COVID-19 suggestive symptoms, history of COVID-19 diagnosis and COVID-19 vaccination status. A venous blood sample was collected from each participant and tested for immunoglobulin G (Ig-G) SARS-CoV-2 antibody titers using the enzyme-linked immunosorbent assay (ELISA). Seroprevalence was 31.1% in the Bantul Regency: 34.2% in semi-urban and 29.9% in urban villages. However, there is no significant proportion difference between both areas. A significant difference was reported in the age group. Participants in the 55-64 age group demonstrated the highest seroprevalence (43.7%; p=0.00), with a higher risk compared to the other age group (aOR= 3.79; 95% CI, 1.46-9.85, p<0.05). Seroprevalence in the unvaccinated participants was 29.9%. Family clusters accounted for 10.6% of the total seropositive cases. No significant difference was observed between individual preventive actions and their mobility with seropositivity status. This study observed a discrepancy with COVID-19 confirmed cumulative incidence data reported in the same period (11 out of 1000 population), indicating silent transmission may have occurred within the community. Higher seroprevalence in semi-urban areas rather than urban areas suggests a gap in health services access. Surveillance improvement through testing, tracing, and treatment, particularly in areas with lower access to health services, are necessary, along with more robust implementations of health protocols.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was funded by the Ministry of Research and Technology/National Research and Innovation Agency and Indonesia (BRIN) and the Indonesia Endowment Fund for Education (LPDP) of the Ministry of Finance of the Republic of Indonesia. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Medical and Health Research Ethics Committee of the Faculty of Medicine, Public Health and Nursing Universitas Gadjah Mada with the number KE/1242/12/2020.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data that support the findings of this study are available from the corresponding author upon reasonable request.